Safeguard Scientifics, Inc.
SFES · Other OTC · USD
0,63USD
+0,03 (+5,00 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 0,59
- Vortag
- 0,60
- Tagesspanne
- 0,59 – 0,63
- 52 Wochen
- 0,22 – 1,89
- Volumen
- 2000
- Ø Volumen
- 14.442
- Börsenwert
- 10,54 Mio. $
- KGV
- 0,5
- Gewinn je Aktie (TTM)
- 1,17
- Dividendenrendite
- 222,2 %
- Beta
- -0,9
- Nächste Zahlen
- 10. Nov. 2026
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 0 | 0 | 0 | 0 | 0 |
| Herstellungskosten | 436.000 | 374.000 | 319.000 | 271.000 | 229.000 |
| Bruttogewinn | −436.000 | −374.000 | −319.000 | −271.000 | −229.000 |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 1,66 Mio. | 2,25 Mio. | 5,36 Mio. | 4,78 Mio. | 7,15 Mio. |
| Operatives Ergebnis | −2,1 Mio. | −2,63 Mio. | −5,68 Mio. | −4,78 Mio. | −7,15 Mio. |
| EBITDA | −1,66 Mio. | −10,01 Mio. | −9,51 Mio. | −13,99 Mio. | 27,23 Mio. |
| Nettogewinn | 1,73 Mio. | −10,39 Mio. | −9,83 Mio. | −14,26 Mio. | 27 Mio. |
| Gewinn je Aktie (verwässert) | 0,10 | -0,62 | -0,61 | -0,87 | 1,36 |
Bewertung
Letzte 12 Monate
- KGV
- 0,5
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 1,7
- PEG
- 0,0
- Bruttomarge
- 0,0 %
- Operative Marge
- 0,0 %
- Nettomarge
- 0,0 %
- Verschuldungsgrad
- 0,0
- EV/EBITDA
- -3,0
- Eigenkapitalrendite
- 130,9 %
- Kapitalrendite (ROIC)
- −30,1 %
- Free-Cashflow-Rendite
- 0,0 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Operative Marge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Nettomarge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| KGV | 8,0 | -1,4 | -1,3 | -3,6 | 5,4 |
| Kurs-Umsatz-Verhältnis | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Kurs-Buchwert-Verhältnis | 1,2 | 1,5 | 0,6 | 1,5 | 2,9 |
| Verschuldungsgrad | 0,0 | 0,1 | 0,1 | 0,0 | 0,0 |
| Liquidität 3. Grades | 10,1 | 5,8 | 4,8 | 11,8 | 17,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 46,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 4,68 Mio. | 8,28 Mio. | 4,4 Mio. | 38,99 Mio. | 123,04 Mio. |
| EV/EBITDA | -2,8 | -0,8 | -0,5 | -2,8 | 4,5 |
| Eigenkapitalrendite | 14,9 % | −105,7 % | −49,2 % | −41,3 % | 53,4 % |
| Kapitalrendite (ROIC) | −17,8 % | −24,7 % | −26,7 % | −13,2 % | −13,6 % |
| Free-Cashflow-Rendite | 0,0 % | −20,8 % | −26,1 % | −6,4 % | −5,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Bruttogewinn | −16,6 % | −17,2 % | −17,7 % | −18,3 % | +26,4 % |
| Operatives Ergebnis | +20,1 % | +53,8 % | −19,0 % | +33,2 % | +24,4 % |
| Nettogewinn | +116,6 % | −5,7 % | +31,1 % | −152,8 % | +171,8 % |
| Gewinn je Aktie | +116,1 % | −1,6 % | +29,9 % | −164,0 % | +175,1 % |
| Freier Cashflow | 0,0 % | +10,0 % | −1,5 % | +60,0 % | −0,1 % |
| Dividende je Aktie | 0,0 % | −100,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 0 | 0 | 0 |
| Umsatz (Tief – Hoch) | 0 – 0 | 0 – 0 | 0 – 0 |
| Gewinn je Aktie (Ø) | -3,52 | -1,27 | 0,09 |
| Gewinn je Aktie (Tief – Hoch) | -3,52 – -3,52 | -1,27 – -1,27 | 0,09 – 0,09 |
| Analysten | 1 | 1 | 1 |
Quartalszahlen
Nächste Zahlen: 10. Nov. 2026| Aug. 2026 | Mai 2026 | März 2026 | Nov. 2025 | Aug. 2025 | Apr. 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,27 | -0,29 | -0,29 | -0,34 | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,02 | 1,10 | -0,02 | 0,10 | 0,07 | -0,33 | -0,33 | -0,07 |
| Abweichung | +92,59 % | +479,31 % | +94,07 % | +129,41 % | – | – | – | – |
| Umsatz · Tatsächlich | – | – | – | – | – | – | – | – |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 21. Apr. 2026 | – | 1,40 |
| 29. Dez. 2023 | – | 0,35 |
| 20. Dez. 2019 | – | 1,00 |
| 3. Juli 1997 | – | 2,70 |
Aktiensplits
- 27. Aug. 20091:6
- 20. März 20003:1
- 1. Aug. 19962:1
- 15. Sept. 19953:2
- 15. Sept. 19942:1
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
- StepStone Group Holdings LLC6. Dez. 2013 · 10 percent ownerKauf5,61 Mio. Aktien
- StepStone Group Holdings LLC6. Dez. 2013 · 10 percent ownerVerkauf561.155,5 Aktien
- SLATTERY JOSEPH P2. Okt. 2013 · officer: EVP and CFOKauf1 Mio. Aktien
- SLATTERY JOSEPH P2. Okt. 2013 · officer: EVP and CFOVerkauf0 Aktien · 0,40
- StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
- StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
- StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
- SVLSF IV, LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Safeguard Scientifics, Inc., a former private equity and venture capital firm, is no longer actively seeking new investments. Historically, the firm specialized in a broad range of financing activities, including providing capital for company expansion and growth, facilitating management buyouts, executing recapitalizations, driving industry consolidations, and supporting corporate spin-offs. Their investment scope covered both early and growth-stage companies. Typically, Safeguard Scientifics participated in Series A, B, or C funding rounds, with an opportunistic approach to seed-stage investments. Their primary sector focus spanned technology, financial services, and healthcare. Within the technology sphere, their interests were diverse, encompassing areas such as software-as-a-service (SaaS), adtech, digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (FinTech), cloud computing, mobile, social platforms, big data, in-memory computing, and select business services. For these tech ventures, they considered companies requiring up to $25 million in capital. In the healthcare sector, the firm directed its investments towards molecular and point-of-care diagnostics, various medical devices, regenerative medicine, broader medical technology, digital health solutions, healthcare technology, specialized pharmaceuticals, and chosen healthcare services. Geographically, Safeguard Scientifics invested across the entire United States, with a particular emphasis on the Mid-Atlantic region, and also extended its reach into Southeastern Canada. Financial commitments for growth equity financing generally ranged from $5 million to $25 million, while early-stage financings typically saw investments between $5 million and $10 million. The firm's investment strategy often targeted a variety of capital structures, including self-funded (bootstrapped) companies, corporate divisions or business units, and venture capital-backed entities seeking a growth partner. Safeguard Scientifics aimed to be the largest stakeholder in its portfolio companies, typically acquiring an ownership stake between 20% and 50%, though they were flexible and might occasionally take either a majority or a smaller interest. A strong preference existed for companies possessing proprietary technology and intellectual property. Furthermore, the firm routinely sought a Board seat in its invested companies. Founded in 1953 as Lancaster Corporation, the company adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is located in Radnor, Pennsylvania, with an additional presence in Weston, Massachusetts.
Führung
- G. Matthew BarnardGeneral Counsel, Secretary & Compliance Officer
- Mark R. DowChief Executive Officer, Chief Financial Officer & Company Secretary
- Seth ZuckermanSenior Associate of Healthcare
- Alex A. FuiksAssociate
- CEO
- Mark R. Dow
- Mitarbeitende
- 33
- Hauptsitz
- Radnor, PA, US
- Sektor
- Financial Services
- Branche
- Asset Management
- Börsengang
- 17. März 1980
- Website
- safeguardscientifics.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.